【摘要】：目的: 觀察EB病毒(Epstein-Barr virus,EBV)潛伏膜蛋白1 (latent membrane protein 1, LMP-1)抗體在鼻咽癌(nasopharyngeal carcinoma,NPC)患者血清中的水平,探討LMP-1抗體檢測(cè)在NPC血清學(xué)診斷、預(yù)后判斷及腫瘤靶向免疫治療中的臨床意義。 方法: 采用酶聯(lián)免疫吸附試驗(yàn)(Enzyme-linked immunosorbent assay,ELISA)以及免疫印跡(Western blot)方法,以LMP1融合蛋白檢測(cè)61例鼻咽癌患者、30例鼻咽增生性炎患者和55例正常人血清中LMP1抗體水平,比較三組血清抗體水平差異;分析鼻咽癌患者血清LMP1抗體水平與NPC臨床、病理特征的關(guān)系。 結(jié)果: ELISA方法證實(shí),鼻咽癌組LMP1抗體水平(0.618,[0.565-1.070])明顯高于鼻咽增生性炎組( 0.567 , [0.534-0.632] )及正常組( 0.432 ,[0.375-0.476]),鼻咽增生性炎組LMP1抗體水平明顯高于正常組,組間差異均有統(tǒng)計(jì)學(xué)意義(P 0.05)。鼻咽癌組LMP1抗體水平在鼻咽癌不同病理分級(jí)及有無(wú)淋巴結(jié)轉(zhuǎn)移中均無(wú)統(tǒng)計(jì)學(xué)差異(P 0.05)。Western blot方法表明,鼻咽癌組LMP1抗體的表達(dá)較鼻咽增生性炎組及正常組均高。 結(jié)論: 研究結(jié)果提示,鼻咽癌組EB病毒LMP1抗體水平顯著高于鼻咽增生性炎組及正常組,以LMP1融合蛋白進(jìn)行LMP1抗體血清學(xué)檢測(cè)可輔助EB病毒感染的篩查及鼻咽癌的臨床診斷,EBV-LMP1融合蛋白亦可考慮作為腫瘤抗原標(biāo)志物進(jìn)行腫瘤靶向免疫治療。
文內(nèi)圖片：
圖片說(shuō)明：鼻咽癌鼻內(nèi)鏡檢查結(jié)果：鼻咽部新生物增生，，表面不平、壞死
[Abstract]:Aim: to observe the level of EB virus (Epstein-Barr virus,EBV) latent membrane protein 1 (LMP-1) antibody in serum of patients with nasopharyngeal carcinoma (nasopharyngeal carcinoma,NPC), and to explore the clinical significance of LMP-1 antibody detection in serological diagnosis, prognosis and tumor targeted immunotherapy of NPC. Methods: serum LMP1 antibody levels were detected by enzyme-linked immunosorbent assay (Enzyme-linked immunosorbent assay,ELISA) and immunoblotting (Western blot) in 61 patients with nasopharyngeal carcinoma, 30 patients with nasopharyngeal hyperplasia and 55 normal controls, and the relationship between serum LMP1 antibody levels and clinical and pathological features of NPC in patients with nasopharyngeal carcinoma was analyzed. Results: ELISA method confirmed that the level of LMP1 antibody in nasopharyngeal carcinoma group (0.618, [0.565 鈮

本文編號(hào)：2510272